Income Statement
NEUMORA THERAPEUTICS, INC.
NMRA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
- | - | - |
|
Cost of Revenue
|
- | - | - |
|
Gross Profit
|
- | - | - |
|
Operating Expenses
|
241.16 | 263.46 | 252.10 |
|
Research & Development
|
176.07 | 200.93 | 142.72 |
|
Selling, General & Administrative
|
60.09 | 62.54 | 45.48 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-241.16 | -263.46 | -252.10 |
|
Non-Operating Income
|
4.36 | 19.86 | 16.44 |
|
Interest Income
|
8.34 | - | - |
|
Interest Expense
|
3.22 | - | - |
|
Other Non-Op Income / Expense
|
-0.77 | -0.08 | -0.17 |
|
Income Before Tax
|
-236.80 | -243.61 | -235.66 |
|
Income Tax Expense
|
0.13 | 0.18 | 0.27 |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-236.93 | -243.79 | -235.93 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-240.95 | -262.83 | -251.40 |
|
Earnings Per Share (Basic)
|
-1.45 | -1.53 | -3.63 |
|
Diluted EPS
|
-1.45 | -1.53 | -3.63 |
|
Weighted Average Shares
|
163.39 | 159.38 | 65.02 |
|
Diluted Weighted Avg Shares
|
163.39 | 159.38 | 65.02 |
|
Comprehensive Income
|
-236.99 | -243.65 | -235.23 |